어린이 유치 어금니에 지르코니아 크라운을 씌운 후 교합 적응과 씹는 힘 변화를 관찰하는 연구입니다.

All participants will receive pulp therapy and restoration of primary molars with prefabricated zirconia crowns. Bite force and occlusal contacts will be measured using the T-Scan digital occlusal analysis system at baseline, 2 weeks, and 4 weeks post-restoration. Participants act as their own control, with pre-restoration measurements compared to post-restoration outcomes. No comparison or additional study arms are included.

Participants will receive pulp therapy followed by restoration of primary molars with prefabricated zirconia crowns according to standard pediatric dental protocols. Occlusal function and bite force will be assessed using the T-Scan digital occlusal analysis system at baseline, and at 2 and 4 weeks post-restoration. This intervention combines a therapeutic dental procedure with objective, instrumented measurement of occlusal adaptation, allowing participants to act as their own controls. Follow-up visits will monitor crown fit, occlusal contacts, and bite force changes over time.

Pulp Therapy and Zirconia Crown Restoration of Primary Molars with T-Scan Occlusal Analysis

Lama Hatem Mohamed Kamal Belal, BDS

Single dose of JNT-517 or placebo in fasted state.

JNT-517 Suspension

Placebo Suspension

JNT-517 or placebo once or twice daily for 14 days, with first daily dose given after an overnight fast.

Single dose of JNT-517 suspension, JNT-517 tablet in a fasted state, and JNT-517 tablet in a fed state in a sequential, open-label manner. Each treatment is separated by a minimum of 5 half-lives.

JNT-517 Tablet

Single dose of JNT-517 tablet in a fasted state, JNT-517 tablet in a fed state, and JNT-517 suspension in a sequential, open-label manner. Each treatment is separated by a minimum of 5 half-lives.

Single dose of JNT-517 tablet in a fed state, JNT-517 suspension, and JNT-517 tablet in a fasted state in a sequential, open-label manner. Each treatment is separated by a minimum of 5 half-lives.

JNT-517 or placebo daily for 4 weeks. Dose is based on data from Parts A, B, and C.

Placebo Tablet

Otsuka Pharmaceutical Development & Commercialization, Inc.

Patients in both the Phase I and Phase II portion of the study will receive lymphodepleting chemotherapy (unless determined by PI that lymphodepletion is not necessary), followed by a single infusion of the patient-derived SJCAR19 cellular product. The most commonly used lymphodepleting chemotherapy regimen will consist of the agents: Fludarabine and Cyclophosphamide. They will also receive Mesna. Dosing of SJCAR19 on the Phase I study will follow a dose escalation schema, with dose changes based on dose-limiting toxicities. In the Phase II study, SJCAR19 dosing with follow the maximum tolerated dose, as determined in the Phase I portion.

Cells for infusion are prepared using the CliniMACS System.

Cyclophosphamide

Fludarabine

Mesna

The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest.

CliniMACS

CD19- specific CAR engineered autologous T-cells (SJCAR19 product)

transartery chemoembolization and hepatic artery infusion of FOLFOX, simultaneously followed by intravenous of 1200mg atezolizumab plus bevacizumab (15mg/kg)

transartery chemoembolization and artery infusion of FOLFOX, simultaneously followed by intravenous atezolizumab plus bevacizumab

TACE-HACI, plus atezolizumab-bevacizumab

Jiliang Qiu

레어노트에 환자 모임 등록

회원 모집 중

희귀난치성 질환 거짓부갑상선기능저하증 환우회입니다. 환자·보호자 분들과 소통하며 정보 공유를 하는 공간입니다.

<dl class="v3-editor-content-dictionary">
<dt>거짓 부갑상선기능저하증 이란?</dt>
<dd>거짓 부갑상선기능저하증은 부갑상선호르몬 수치는 정상이나 호르몬에 대한 부적절한 반응으로 특징되는 유전 질환입니다. 이러한 반응은 뼈 성장에 영향을 미칠 수 있습니다. X-염색체 연관 혹은 상염색체 우성 유전양식으로 유전됩니다.</dd>
<dd> </dd>
<dd><a href="rarenote://MedicalNewsDetail?id=a30039d0-4a44-44da-b6f1-d1a819dc0100">질환에 대해 더 알아보기</a></dd>
</dl>
'거짓부갑상선기능저하증 환우회' 는 국내 거짓 부갑상선기능저하증 환자와 보호자들을 위한 커뮤니티로, 2024년에 설립되었어요.
네이버 카페로 운영되며, 질환과 관련된 정보를 교류하고 소통할 수 있는 공간입니다.

거짓부갑상선기능저하증 환우회

네이버 카페

여러분은 혼자가 아닙니다. 힘내세요(Stay Strong), 계속 나아갑시다(Press on).

<dl class="v3-editor-content-dictionary">
<dt>알라질 증후군 이란?</dt>
<dd>알라질 증후군(Alagille's syndrome)은 간내 담도의 수가 현저하게 감소하고 담즙정체를 나타내며 심혈관계, 골격계, 안구, 안면, 췌장, 신경발달의 장애를 동반할 수 있는 증후군입니다.</dd>
<dd> </dd>
<dd><a href="rarenote://MedicalNewsDetail?id=d0179964-8d3b-41be-b7ac-e61810909f13">질환에 대해 더 알아보기</a></dd>
</dl>
'알라질 증후군 환우모임' 밴드는 국내 알라질 증후군 환자와 보호자들을 위한 커뮤니티로, 2025년에 설립되었어요.
네이버 밴드로 운영되며, 알라질 증후군 관련 정보를 교류하고 소통할 수 있는 공간입니다.

알라질 증후군 환우모임

네이버 밴드

비정형 용혈요독증후군 환우·보호자들이 모여있는 오픈 채팅방으로 질환 및 치료에 대한 정보를 공유하고, 일상을 공감합니다.

비정형 용혈요독증후군(aHUS) 카카오톡 오픈채팅방

오픈 채팅방

저인산효소증 환우·보호자들이 모여있는 오픈 채팅방으로 질환 및 치료에 대한 정보를 공유하고, 일상을 공감합니다.

임상시험 현황

T-스캔 교합 분석을 이용한 유치 어금니의 치수 치료 및 지르코니아 크라운 수복

JNT-517 현탁액, 위약 현탁액, JNT-517 정제, 위약 정제

사이클로포스파마이드, 플루다라빈, 메스나, 클리니맥스, CD19 특이적 CAR 엔지니어링 자가 T 세포(SJCAR19 제품)

TACE-HACI, + 아테졸리주맙-베바시주맙

환자 모임 정보